Study of the Efficacy of Chloroquine in the Treatment of Ductal Carcinoma in Situ (The PINC Trial)
Status: COMPLETED
Study type: INTERVENTIONAL
Conditions: Carcinoma, Intraductal, Noninfiltrating|DCIS|Ductal Carcinoma In Situ
Interventions: DRUG: Chloroquine Standard Dose (500mg/week)|DRUG: Chloroquine Low Dose (250mg/week)|PROCEDURE: Breast Biopsy
Sponsor: Inova Health Care Services
Collaborators: George Mason University|University of Pittsburgh Medical Center|United States Department of Defense|U.S. Army Medical Research and Development Command